I. Nesthus

发表

Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma.

T. Hervig, G. Melve, P. Lassalle, 2011, Cytotherapy.

Cellular immune responses in multiple myeloma patients with treatment-induced cytopenia early after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.

Ø. Bruserud, I. Nesthus, M. Sjo, 2004, Leukemia research.

A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.

G. Juliusson, M. Björkholm, B. Gustavsson, 2003, Leukemia research.

Malignancy: Insulin-like Growth Factor-1 (IGF-1) is a Costimulator of the Expansion of Lineage Committed Cells Derived from Peripheral Blood Mobilized CD34+ Cells in Multiple Myeloma Patients.

T. Hervig, J. Olweus, R. Bjerknes, 1999, Hematology.

Insulin-like Growth Factor-1 (IGF-1) is a Costimulator of the Expansion of Lineage Committed Cells Derived from Peripheral Blood Mobilized CD34(+) Cells in Multiple Myeloma Patients.

T. Hervig, Ø. Bruserud, J. Olweus, 1999, Hematology.

Long‐term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells

Ø. Bruserud, E. Ersvær, A. Ryningen, 2009, Transfusion.

Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts: studies of allostimulated interferon-γ secretion

Ø. Bruserud, S. Berentsen, I. Nesthus, 1997, Cancer Immunology, Immunotherapy.

Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B

A. Waage, A. Sundan, I. Turesson, 2015, Cell Communication and Signaling.

Impact of age on survival after intensive therapy for multiple myeloma: a population‐based study by the Nordic Myeloma Study Group

U. Mellqvist, H. Johnsen, O. Linder, 2006, British journal of haematology.

Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.

H. Johnsen, E. Holmberg, J. Lamvik, 2000, Blood.

A Randomised Placebo Controlled Study With Melphalan/Prednisone Vs Melphalan/Prednisone/Thalidomide: Quality Of Life And Toxicity

P. Fayers, U. Mellqvist, G. Juliusson, 2008 .

Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial

U. Mellqvist, O. Linder, H. Nahi, 2009 .

Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support

T. G. S. Group, J. Lamvik, L. Knudsen, 2001, Medical oncology.

A multi-centre prospective study of febrile neutropenia in Norway: Microbiological findings and antimicrobial susceptibility

S. Harthug, N. Langeland, A. Digranes, 2005, Scandinavian journal of infectious diseases.

Survival in 86 patients, aged 15–60, with primary acute myelogenous leukemia, treated with a common program in the Norwegian health regions I, III, IV and V in the period 1990–1995

J. Lamvik, M. Abdelnoor, L. Brinch, 1997, European journal of haematology.

Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation

Ø. Bruserud, Ç. A. Akkök, I. Nesthus, 2008, Transfusion.

Activin A inhibits BMP-signaling by binding ACVR 2 A and ACVR 2 B

A. Waage, A. Sundan, I. Turesson, 2015 .

Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.

U. Mellqvist, H. Johnsen, O. Linder, 2006, Haematologica.

Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia

Ø. Bruserud, I. Nesthus, M. Sjo, 2004, Cancer Immunology, Immunotherapy.

Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia.

Ø. Bruserud, G. Pawelec, O. Brustugun, 1995, Leukemia.

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.

P. Fayers, U. Mellqvist, O. Linder, 2010, Blood.

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.

P. Fayers, O. Linder, G. Juliusson, 2010, The Lancet. Oncology.

Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study.

S. Vollset, P. Ueland, S. Vollset, 1996, The Journal of clinical investigation.

Insulin-like Growth Factor-1 (IGF-1) is a Costimulator of the Expansion of Lineage Committed Cells Derived from Peripheral Blood Mobilized CD34(+) Cells in Multiple Myeloma Patients.

I. Nesthus, Øystein Bruserud, Robert Bjerknes, 1999, Hematology.